These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15058529)

  • 1. The race to block TNF-alpha: the caution flag is raised again.
    Kaplan G; Panaccione R
    Inflamm Bowel Dis; 2004 Jan; 10(1):61-2. PubMed ID: 15058529
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 5. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab).
    Li Gobbi F; Benucci M; Del Rosso A
    J Clin Rheumatol; 2005 Apr; 11(2):119-20. PubMed ID: 16357717
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
    Curtis JR; Patkar N; Xie A; Martin C; Allison JJ; Saag M; Shatin D; Saag KG
    Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 8. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat.
    O'Dell JR
    Mayo Clin Proc; 2001 Jun; 76(6):573-5. PubMed ID: 11393494
    [No Abstract]   [Full Text] [Related]  

  • 9. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
    Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
    Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
    [No Abstract]   [Full Text] [Related]  

  • 10. Pneumocystis pneumonia associated with infliximab in Japan.
    Harigai M; Koike R; Miyasaka N;
    N Engl J Med; 2007 Nov; 357(18):1874-6. PubMed ID: 17978303
    [No Abstract]   [Full Text] [Related]  

  • 11. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.
    Mori S; Imamura F; Kiyofuji C; Sugimoto M
    Mod Rheumatol; 2006; 16(4):251-5. PubMed ID: 16906378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late onset of long-lasting fever as a sole complication of treatment with anti-TNFalpha.
    Tassiopoulos S; Benopoulou O; Mytilineou E; Andreopoulos A; Vaiopoulos G
    Clin Exp Rheumatol; 2005; 23(1):122-3. PubMed ID: 15789902
    [No Abstract]   [Full Text] [Related]  

  • 16. [Infliximab for therapy of rheumatoid arthritis].
    Amano K
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():517-20. PubMed ID: 15799410
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab.
    Hrycaj P; Korczowska I; Łacki JK
    Rheumatology (Oxford); 2003 May; 42(5):702-3. PubMed ID: 12709557
    [No Abstract]   [Full Text] [Related]  

  • 18. Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
    Asano Y; Kano Y; Shiohara T
    Acta Derm Venereol; 2008; 88(2):183-4. PubMed ID: 18311458
    [No Abstract]   [Full Text] [Related]  

  • 19. Polymyositis associated with infliximab treatment for rheumatoid arthritis.
    Urata Y; Wakai Y; Kowatari K; Nitobe T; Mizushima Y
    Mod Rheumatol; 2006; 16(6):410-1. PubMed ID: 17165006
    [No Abstract]   [Full Text] [Related]  

  • 20. Extraarticular rheumatoid arthritis and drug-induced syndromes: understanding the role of tumor necrosis factor inhibitors.
    Bruyn GA
    J Rheumatol; 2004 Jul; 31(7):1461; author reply 1462. PubMed ID: 15229972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.